Skip Navigation



NDT Advance Access published online on December 8, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm865
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/2/431    most recent
gfm865v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Steinman, T. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Steinman, T. I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Renal and Cardiac Effects of Antihypertensive Treatment with Ramipril Versus Metoprolol in Autosomal Dominant Polycystic Kidney Disease

Theodore I. Steinman

Renal Division, Beth Israel Deaconess Medical Center, Harvard Medical School, MA, USA

Correspondence and offprint requests to: Theodore I. Steinman, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue ST 220, Boston, MA 02215, USA. Tel: +1-617-667-5278; Fax: +1-617-975-5595; E-mail: tsteinma@bidmc.harvard.edu

Keywords: polycystic kidney disease; hypertension; ACE inhibitors versus beta blockers

The first 10% of the full text of this article appears below.

Autosomal dominant polycystic kidney disease (ADPKD) affects ~12.5 million people worldwide. Forty percent of patients are diagnosed by 45 years of age. ADPKD is the fourth most common cause for end-stage renal disease (ESRD) worldwide and this disease accounts for 5–10% of renal transplant recipients [1,2]. Therefore, any therapeutic modality that can slow down the natural course history of this disease would have a significant impact on patients’ well-being and would be financially cost-effective. The manuscript by Zeltner et al. in this issue attempts to determine if there is a difference between an angiotensin-converting enzyme (ACE) inhibitor (Ramipril) and a beta blocker (Metoprolol) when employing first-line therapy in ADPKD patients with hypertension.

The study has a number of limitations; some of them recognized by the authors that could influence the conclusion are noted as follows:

1.  Small number of study subjects that lead to a Type . . . [Full Text of this Article]



   Clinical trials to slow progression of ADPKD
 


   Activation of the RAAS in ADPKD
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?